SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-006834
Filing Date
2023-03-09
Accepted
2023-03-09 07:14:13
Documents
14
Period of Report
2023-03-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fulc-20230309.htm   iXBRL 8-K 57567
2 EX-99.1 fulc-ex99_1.htm EX-99 178678
3 GRAPHIC img189780767_0.jpg GRAPHIC 2981
  Complete submission text file 0000950170-23-006834.txt   377967

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fulc-20230309_lab.xml EX-101.LAB 14018
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fulc-20230309.xsd EX-101.SCH 2472
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fulc-20230309_pre.xml EX-101.PRE 10289
8 EXTRACTED XBRL INSTANCE DOCUMENT fulc-20230309_htm.xml XML 4936
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

IRS No.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38978 | Film No.: 23718162
SIC: 2834 Pharmaceutical Preparations